Loading clinical trials...
Loading clinical trials...
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, Designed to Determine the Efficacy, Safety, and Tolerability of Intramuscular Administration of Allogeneic PLX-PAD Cells for the Treatment of Muscle Injury Following Arthroplasty for Hip Fracture
Conditions
Interventions
PLX-PAD
Placebo
Locations
17
United States
University Of California Davis,4860 Y Street
Sacramento, California, United States
Denver Metro Orthopedics, P.C. 499 E. Hampden Avenue, Suite 140 Englewood, CO 80113
Denver, Colorado, United States
ANTRIA, INC,300 Indian Springs Road,Indiana
Indiana, Pennsylvania, United States
MHAT "Ljulin" Department of Orthopedy and Traumatology
Sofia, Bulgaria
MHAT "Serdika" Department of Orthopedy and Traumatology
Sofia, Bulgaria
Military Medical Academy
Sofia, Bulgaria
Start Date
July 26, 2018
Primary Completion Date
April 29, 2022
Completion Date
September 6, 2023
Last Updated
September 28, 2023
NCT07350044
NCT06565910
NCT07442721
NCT06773000
NCT07432737
NCT06521671
Lead Sponsor
Pluristem Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions